HuGE Literature Finder
Records
1
-
4
First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations. BMC medicine 2023 1 21 (1): 2. Wang Xuan, Luo Zhiguo, Chen Jing, Chen Yu, Ji Dongmei, Fan Li, Chen Ling, Zhao Qian, Hu Pei, Sun Peng, Jia Zhongwei, Guo Jun, Si |
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data. Scientific reports 2021 7 11 (1): 14321. Fernández Montes Ana, Carmona-Bayonas Alberto, Jimenez-Fonseca Paula, Vázquez Rivera Francisca, Martinez Lago Nieves, Covela Rúa Marta, Cousillas Castiñeiras Antía, Gonzalez Villarroel Paula, De la Cámara Gómez Juan, Méndez José Carlos Méndez, Carriles Fernández Carmen, Sanchez Cánovas Manuel, Garcia García Tere |
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. British journal of cancer 2019 Jul . Elez Elena, Pericay Carles, Valladares-Ayerbes Manuel, Bando Inmaculada, Safont Maria Jose, Gallego Javier, Grávalos Cristina, Arrivi Antonio, Carrato Alfredo, Conde Verónica, Ortiz Maria José, López Carlos, Alonso Beatriz, Ruiz de Mena Inmaculada, Díaz-Rubio Eduardo, Tabernero Josep, Aranda Enriq |
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013 Aug 24 (8): 2062-7. Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: